Form 4: Rhythm Pharmaceuticals Executive Joseph Shulman Reports Stock Transactions

Chief Technical Officer Joseph Shulman reports acquisition and disposal of Rhythm Pharmaceuticals stock and derivative securities.

Summary

• Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, reported transactions involving the company's stock.
• On February 16, 2025, Shulman acquired 4,125 shares through the vesting of restricted stock units and disposed of 4,125 shares.
• On February 19, 2025, Shulman sold 1,228 shares at a price of $57.22 per share.
• Shulman also acquired 25,000 restricted stock units and 37,500 stock options on February 14, 2025.
• Following these transactions, Shulman beneficially owns 8,509 shares of common stock, 25,000 restricted stock units granted on February 14, 2025, 37,500 stock options granted on February 14, 2025, and 12,375 restricted stock units granted on February 16, 2025.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into their trading activities and holdings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
• Employees may be affected by the vesting of stock options and restricted stock units.

Key Dates

Keywords

Form 4, Rhythm Pharmaceuticals, RYTM, insider trading, stock options, restricted stock units, Joseph Shulman, Chief Technical Officer, stock sale, stock acquisition